By Vickys Kourlibini
The first stop of the 356 million euro business plan for the pharmaceutical industry DEMO ABEE, which is the largest producer of injectables in Greece, is Thessaloniki. The pharmaceutical industry yesterday inaugurated the research and development center in Thermi, which has already begun to be staffed with specialized research staff, with the aim of developing five active substances and 21 final pharmaceutical products per year (by the end of 2027, to have completed the development of 125 new preparations ).
The center is one of the largest laboratories in the country, with an area of 2,400 sq.m., and is part of the 2021-2017 investment plan (announced in November) also includes: the expansion of production dynamics in Kryoneri Attica, four raw material production units and six final product production units in Tripoli and a monoclonal antibody development unit and BioAcademy in Attica. The start of the Bio-Academy is foreseen with the completion of the facility, while the scientists from abroad have already started to be recruited for this purpose as well as for the design of the overall facility.
The research center in Thermi
One hundred researchers will be employed in the first phase to reach two hundred, as the CEO of DEMO ABEE Dimitris Demos said during the inauguration.
“Greece has the potential to become the largest research hub in the Balkans,” he noted, emphasizing that the investment is another means in the direction of brain gain. “We want young people with dreams to stay in Greece, the next Bourla not to leave Thessaloniki”, giving as an example the CEO of Pfizer who grew up in the co-capital, immigrated and returned to his country to invest in pharmaceutical research (with the center digital innovation of Pfizer).
The laboratory in Thessaloniki, as Mr. Demos said, consists of 13 different laboratories and a nuclear coordination laboratory, the first in a private company.
The business plan
The investment plan includes the research and development of raw materials and finished drugs in the center in Thermi, raw materials and finished drugs in Tripoli and biotechnological drugs in Agios Stefanos. It is the largest, he noted, investment project in the pharmaceutical field and one of the largest industrial projects in the country.
In fact, DEMO acquires the ability to produce all the pharmaceutical forms and categories of injectables that exist today, while the size of the production facilities in Tripoli is such that it can cover 20% of the needs of nursing institutions throughout Europe for the products that will produces.
In Tripoli, the industrial complex will have a total building area of 74,000 m2 and produce 200 tons of raw material and 250 million pieces of finished pharmaceuticals per year. With the completion of this investment, and in full operation, 450 new jobs are expected to be created.
The pharmaceutical industry DEMO was founded in 1965 and is active in the development, production and sale of pharmaceutical products. The company is experiencing significant growth in all sectors and is first in injectable product production facilities, in hospital sales (in number of units) in Greece and among the first 100 industries in the country.
Source: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
